Time filter

Source Type

Professor de Winter commented, "MiStent met the primary non-inferiority endpoint of target lesion failure (TLF) at 12 months, with numerically lower TLF and target lesion revascularization (TLR) rates. TLR rates for MiStent were numerically lower at all time points following the procedure, and by one year that difference grew to 1.2%. These results speak to the potential value of slower, controlled drug release allowing for sustained drug presence. These trial results, in conjunction with the five-year results from the DESSOLVE I and II studies, provide further evidence of the potential value of this technology relative to current DES performance expectations from the perspectives of both safety and efficacy." DESSOLVE III is a prospective, balanced, randomized, controlled, single-blind, multi-center all-comers study comprising 1,400 patients. Enrollment was completed in December 2015, and today's presentation highlighted twelve-month primary endpoint outcomes. The study is being conducted independently by the European Cardiovascular Research Institute, Rotterdam, The Netherlands and is supported by Micell Technologies. The study design and conduct were overseen by a steering committee including Professors Patrick Serruys, Robbert de Winter, and William Wijns. Patients in this trial suffered from symptomatic coronary artery disease, including those with chronic stable angina, silent ischemia, or acute coronary syndrome (including non-ST-elevation myocardial infarction and ST-elevation myocardial infarction), and qualified for percutaneous coronary interventions. The primary endpoint for this trial was a non-inferiority comparison of TLF for the MiStent group versus the Xience group at 12 months post-procedure. Dennis Donohoe, M.D., Micell's chief medical advisor, said, "These results appear to validate the unique premise of Micell's supercritical fluid technology platform, which allows drug in micro-crystalline form to be combined with a fast-dissolving polymer and applied as a coating on an ultra-thin-strut cobalt chromium stent. These unique features have the potential to offer meaningful clinical and economic benefits to patients and the healthcare system." In a session on novel drug-eluting stent technologies, Professor Krzysztof Milewski, lead investigator for the DESSOLVE III OCT sub-study, highlighted positive outcomes from assessments of optical coherence tomography (OCT) images from MiStent and Xience patients at six months. Neointimal hyperplasia volume obstruction was statistically lower for MiStent (15.0±4.1% vs 18.9±6.2%; p<0.01). Similarly, both abluminal neointimal hyperplasia volume and area were significantly better with MiStent by 13.3 mm3 (p=0.02) and 0.33 mm2 (p<0.01), respectively. Both groups demonstrated equal and almost complete strut coverage. "We observed a statistically significant difference in favor of MiStent," confirmed Professor Milewski, M.D., Ph.D., General Director, Center for Research and Development for the American Heart of Poland S.A. "These OCT data further demonstrate that the unique pharmacokinetics of MiStent, with its micro-crystalline sirolimus, reduce the factors that lead to late lumen loss requiring vessel revascularization." Additional data and an overview of the rationale and design of the OCT assessments presented by Professor Milewski will be the subject of a late breaking trial submission, also at EuroPCR, on May 18. Professor Milewski will present, "OCT and IVUS Imaging for Evaluation of Stent-Based Therapies: DESSOLVE III, a Randomised OCT Sub-Study Comparison of Xience vs MiStent." MiStent is designed to optimize clinical performance and healing in patients with coronary artery disease. The rapidly absorbable coating of MiStent, which contains micro-crystalline drug (sirolimus) and an absorbable polymer, is intended to precisely and consistently provide for extended local drug delivery and limit the duration of polymer exposure. These characteristics potentially reduce the safety risks associated with currently commercially available drug-eluting stents and improve long-term clinical outcomes. MiStent has received CE marking, but is not approved for sale in the United States. This press release contains forward-looking statements that can be identified by the fact that they do not relate strictly to historical or current facts. Forward-looking statements include words such as "anticipates," "estimates," "expects," "projects," "intends," "plans," "believes" and words and terms of similar substance in connection with the results of a post-marketing clinical program and the commercialization and sale of MiStent in Europe and other markets. We caution readers that the forward-looking statements contained in this press release are predictions based on our current analysis of, and expectations about, future events and speak only as of the date of this press release. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, including, but not limited to, the following: the results of any further clinical trials and studies; our ability to obtain regulatory approval of the MiStent in other jurisdictions; the successful development and commercialization of MiStent in Europe and other markets; the ability of MiStent to effectively and successfully compete with currently commercially available drug-eluting stent technologies in Europe and other markets; and our ability to maintain and protect our proprietary stent coating technology. Actual results, performance or achievements could differ materially and adversely from those expressed or implied by any forward-looking statement contained in this press release. Micell, Micell Technologies, the Micell Logo, and MiStent are among the trademarks of Micell Technologies, Inc. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/micell-technologies-announces-mistent-achieved-primary-endpoint-in-all-comers-randomized-clinical-trial-versus-xience-300458313.html


Professor de Winter commented, "MiStent met the primary non-inferiority endpoint of target lesion failure (TLF) at 12 months, with numerically lower TLF and target lesion revascularization (TLR) rates. TLR rates for MiStent were numerically lower at all time points following the procedure, and by one year that difference grew to 1.2%. These results speak to the potential value of slower, controlled drug release allowing for sustained drug presence. These trial results, in conjunction with the five-year results from the DESSOLVE I and II studies, provide further evidence of the potential value of this technology relative to current DES performance expectations from the perspectives of both safety and efficacy." DESSOLVE III is a prospective, balanced, randomized, controlled, single-blind, multi-center all-comers study comprising 1,400 patients. Enrollment was completed in December 2015, and today's presentation highlighted twelve-month primary endpoint outcomes. The study is being conducted independently by the European Cardiovascular Research Institute, Rotterdam, The Netherlands and is supported by Micell Technologies. The study design and conduct were overseen by a steering committee including Professors Patrick Serruys, Robbert de Winter, and William Wijns. Patients in this trial suffered from symptomatic coronary artery disease, including those with chronic stable angina, silent ischemia, or acute coronary syndrome (including non-ST-elevation myocardial infarction and ST-elevation myocardial infarction), and qualified for percutaneous coronary interventions. The primary endpoint for this trial was a non-inferiority comparison of TLF for the MiStent group versus the Xience group at 12 months post-procedure. Dennis Donohoe, M.D., Micell's chief medical advisor, said, "These results appear to validate the unique premise of Micell's supercritical fluid technology platform, which allows drug in micro-crystalline form to be combined with a fast-dissolving polymer and applied as a coating on an ultra-thin-strut cobalt chromium stent. These unique features have the potential to offer meaningful clinical and economic benefits to patients and the healthcare system." In a session on novel drug-eluting stent technologies, Professor Krzysztof Milewski, lead investigator for the DESSOLVE III OCT sub-study, highlighted positive outcomes from assessments of optical coherence tomography (OCT) images from MiStent and Xience patients at six months. Neointimal hyperplasia volume obstruction was statistically lower for MiStent (15.0±4.1% vs 18.9±6.2%; p<0.01). Similarly, both abluminal neointimal hyperplasia volume and area were significantly better with MiStent by 13.3 mm3 (p=0.02) and 0.33 mm2 (p<0.01), respectively. Both groups demonstrated equal and almost complete strut coverage. "We observed a statistically significant difference in favor of MiStent," confirmed Professor Milewski, M.D., Ph.D., General Director, Center for Research and Development for the American Heart of Poland S.A. "These OCT data further demonstrate that the unique pharmacokinetics of MiStent, with its micro-crystalline sirolimus, reduce the factors that lead to late lumen loss requiring vessel revascularization." Additional data and an overview of the rationale and design of the OCT assessments presented by Professor Milewski will be the subject of a late breaking trial submission, also at EuroPCR, on May 18. Professor Milewski will present, "OCT and IVUS Imaging for Evaluation of Stent-Based Therapies: DESSOLVE III, a Randomised OCT Sub-Study Comparison of Xience vs MiStent." MiStent is designed to optimize clinical performance and healing in patients with coronary artery disease. The rapidly absorbable coating of MiStent, which contains micro-crystalline drug (sirolimus) and an absorbable polymer, is intended to precisely and consistently provide for extended local drug delivery and limit the duration of polymer exposure. These characteristics potentially reduce the safety risks associated with currently commercially available drug-eluting stents and improve long-term clinical outcomes. MiStent has received CE marking, but is not approved for sale in the United States. This press release contains forward-looking statements that can be identified by the fact that they do not relate strictly to historical or current facts. Forward-looking statements include words such as "anticipates," "estimates," "expects," "projects," "intends," "plans," "believes" and words and terms of similar substance in connection with the results of a post-marketing clinical program and the commercialization and sale of MiStent in Europe and other markets. We caution readers that the forward-looking statements contained in this press release are predictions based on our current analysis of, and expectations about, future events and speak only as of the date of this press release. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, including, but not limited to, the following: the results of any further clinical trials and studies; our ability to obtain regulatory approval of the MiStent in other jurisdictions; the successful development and commercialization of MiStent in Europe and other markets; the ability of MiStent to effectively and successfully compete with currently commercially available drug-eluting stent technologies in Europe and other markets; and our ability to maintain and protect our proprietary stent coating technology. Actual results, performance or achievements could differ materially and adversely from those expressed or implied by any forward-looking statement contained in this press release. Micell, Micell Technologies, the Micell Logo, and MiStent are among the trademarks of Micell Technologies, Inc.


- MiStent Data the Subject of Three EuroPCR 2017 Presentations - PARIS, May 16, 2017 /PRNewswire/ -- Micell Technologies announced today at the late-breaking trial session of EuroPCR – the official congress of the European Association of Percutaneous Cardiovascular Interventions – positive twelve-month data from its DESSOLVE III clinical trial. The study met its primary endpoint, showing non-inferior safety and effectiveness outcomes in a complex patient population for the MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent) versus the Xience® Everolimus Eluting Coronary Stent System (Xience). Professor Robbert J. de Winter, M.D., Ph.D., Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands presented the data. Professor de Winter commented, "MiStent met the primary non-inferiority endpoint of target lesion failure (TLF) at 12 months, with numerically lower TLF and target lesion revascularization (TLR) rates. TLR rates for MiStent were numerically lower at all time points following the procedure, and by one year that difference grew to 1.2%. These results speak to the potential value of slower, controlled drug release allowing for sustained drug presence. These trial results, in conjunction with the five-year results from the DESSOLVE I and II studies, provide further evidence of the potential value of this technology relative to current DES performance expectations from the perspectives of both safety and efficacy." DESSOLVE III is a prospective, balanced, randomized, controlled, single-blind, multi-center all-comers study comprising 1,400 patients. Enrollment was completed in December 2015, and today's presentation highlighted twelve-month primary endpoint outcomes. The study is being conducted independently by the European Cardiovascular Research Institute, Rotterdam, The Netherlands and is supported by Micell Technologies. The study design and conduct were overseen by a steering committee including Professors Patrick Serruys, Robbert de Winter, and William Wijns. Patients in this trial suffered from symptomatic coronary artery disease, including those with chronic stable angina, silent ischemia, or acute coronary syndrome (including non-ST-elevation myocardial infarction and ST-elevation myocardial infarction), and qualified for percutaneous coronary interventions. The primary endpoint for this trial was a non-inferiority comparison of TLF for the MiStent group versus the Xience group at 12 months post-procedure. Dennis Donohoe, M.D., Micell's chief medical advisor, said, "These results appear to validate the unique premise of Micell's supercritical fluid technology platform, which allows drug in micro-crystalline form to be combined with a fast-dissolving polymer and applied as a coating on an ultra-thin-strut cobalt chromium stent. These unique features have the potential to offer meaningful clinical and economic benefits to patients and the healthcare system." In a session on novel drug-eluting stent technologies, Professor Krzysztof Milewski, lead investigator for the DESSOLVE III OCT sub-study, highlighted positive outcomes from assessments of optical coherence tomography (OCT) images from MiStent and Xience patients at six months. Neointimal hyperplasia volume obstruction was statistically lower for MiStent (15.0±4.1% vs 18.9±6.2%; p<0.01). Similarly, both abluminal neointimal hyperplasia volume and area were significantly better with MiStent by 13.3 mm3 (p=0.02) and 0.33 mm2 (p<0.01), respectively. Both groups demonstrated equal and almost complete strut coverage. "We observed a statistically significant difference in favor of MiStent," confirmed Professor Milewski, M.D., Ph.D., General Director, Center for Research and Development for the American Heart of Poland S.A. "These OCT data further demonstrate that the unique pharmacokinetics of MiStent, with its micro-crystalline sirolimus, reduce the factors that lead to late lumen loss requiring vessel revascularization." Additional data and an overview of the rationale and design of the OCT assessments presented by Professor Milewski will be the subject of a late breaking trial submission, also at EuroPCR, on May 18. Professor Milewski will present, "OCT and IVUS Imaging for Evaluation of Stent-Based Therapies: DESSOLVE III, a Randomised OCT Sub-Study Comparison of Xience vs MiStent." MiStent is designed to optimize clinical performance and healing in patients with coronary artery disease. The rapidly absorbable coating of MiStent, which contains micro-crystalline drug (sirolimus) and an absorbable polymer, is intended to precisely and consistently provide for extended local drug delivery and limit the duration of polymer exposure. These characteristics potentially reduce the safety risks associated with currently commercially available drug-eluting stents and improve long-term clinical outcomes. MiStent has received CE marking, but is not approved for sale in the United States. This press release contains forward-looking statements that can be identified by the fact that they do not relate strictly to historical or current facts. Forward-looking statements include words such as "anticipates," "estimates," "expects," "projects," "intends," "plans," "believes" and words and terms of similar substance in connection with the results of a post-marketing clinical program and the commercialization and sale of MiStent in Europe and other markets. We caution readers that the forward-looking statements contained in this press release are predictions based on our current analysis of, and expectations about, future events and speak only as of the date of this press release. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, including, but not limited to, the following: the results of any further clinical trials and studies; our ability to obtain regulatory approval of the MiStent in other jurisdictions; the successful development and commercialization of MiStent in Europe and other markets; the ability of MiStent to effectively and successfully compete with currently commercially available drug-eluting stent technologies in Europe and other markets; and our ability to maintain and protect our proprietary stent coating technology. Actual results, performance or achievements could differ materially and adversely from those expressed or implied by any forward-looking statement contained in this press release. Micell, Micell Technologies, the Micell Logo, and MiStent are among the trademarks of Micell Technologies, Inc.


News Article | November 9, 2016
Site: www.24-7pressrelease.com

BOWLING GREEN, KY, November 09, 2016 /24-7PressRelease/ -- HRD Strategies, Inc., announced today the opening of the Bowling Green Regional Office. The regional office will provide client centric solutions in Human Resource Management, Training and Development, Talent Management, Executive Coaching, and Organizational Development, to clients across South Central Kentucky and Nashville, Tennessee. Michael Lovett, Founder and Senior Partner, is leading the expansion. "Over the last few years, HRD Strategies led a workforce development initiative in partnership with WKU Glasgow. We built lasting relationships with business, government and nonprofit leaders in the region. Through this effort, our firm became equally invested in the region's economic success and felt it was critical to have a local presence," Founder and Senior Partner, Michael Lovett, shared. With the opening of the new regional office, three new Strategic Human Resource Advisors have joined the team - Cindy Hines, Dana Cosby and David Harbison. Cindy Hines, MBA, SPHR, SHRM-SCP has joined the firm to grow the organizational development practice in the region. Cindy Hines brings extensive experience as a human resources and organizational development leader including industry experience in fast-paced consumer goods and healthcare. Cindy comments "I'm excited to be back in my home state of Kentucky and look forward to helping local organizations maximize their bottom line by providing customized solutions to their business and human resource needs. HRD Strategies is positioned to positively impact the companies based in our region." Dana Cosby, Ph.D., GPHR, CCP, SPHR, SHRM-SCP has joined the team as a Strategic Human Resource Advisor, as well. Dana's experience includes leadership roles in both private and public sectors, consulting and academics. She held an executive role with a billion-dollar multi-national organization with oversight for a number of corporate functions. Dana shares her enthusiasm about joining the firm, "After years of partnering with HRD Strategies, it is my privilege to join a team of industry leaders with a shared purpose to create and develop talent resulting in a pipeline of great employees." David Harbison, SPHR, SHRM-SCP brings over 25 years of combined operational and human resource experience. David excels at strategic planning, organizational development, leadership coaching, exempt-level recruiting, talent management as well as workforce development and analysis. "While HRD Strategies, Inc. serves organizations across the country, we believe in our community and that our work will support and add value to businesses in this region," shares David. Michael Lovett comments, "With Cindy, Dana and David on the team, we are equipped to deliver outstanding solutions to our local clients and others in this region. This will elevate the level of custom designed services we can provide to our customers." The Bowling Green Regional office is located at the WKU Center for Research and Development, Suite 317. HRD Strategies is proud to be working within the same space as other small businesses in the region as part of the WKU Small Business Accelerator. Headquartered in Greensboro, North Carolina, HRD Strategies, Inc. has 25 years of experience as an industry leader and is repeatedly recognized as a leading Organizational Effectiveness and Human Resources firm. The Greensboro based professionals, Julie Copeland, SPHR, SHRM-SCP and Michele Price,SPHR, SHRM-SCP, led by President and Managing Partner, Nina Lovett, SPHR, SHRM-SCP, will continue to provide their expertise to local and national clients. "Our team in Greensboro is excited about the firm's growth and committed to continue to serve as trusted business partners for our clients," shared Nina. About HRD Strategies, Inc. HRD Strategies, Inc. delivers innovative, customized solutions in Human Resource Management and Organizational Development. In the HR field, HRD provides a full range of services to include interim HR support, Investigations and HR Audits, Recruiting and Hiring, Performance Management, and HR Start Up. Additionally, Organizational Development value-added services include Training and Development, Executive and Management Recruitment, Training and Coaching, Career Transition and Outplacement Support, Individual Assessment and Feedback, and Team Alignment. HRD Strategies partners with clients to develop and execute organizational strategies to best fit their needs - ultimately maximizing bottom-line business results. HRD Strategies has launched solutions across for-profit, nonprofit and public sectors. They are a full-service partner providing solutions across all aspects of human capital management. To learn more, visit http://www.hrdstrategies.com.


News Article | December 20, 2016
Site: www.eurekalert.org

Researchers develop a novel route to synthesize melanin, the primary pigment in mammals, and to facilitate its use in sensors and other applications Bioelectronics, sometimes called the next medical frontier, is a research field that combines electronics and biology to develop miniaturized implantable devices capable of altering and controlling electrical signals in the human body. Large corporations are increasingly interested: a joint venture in the field has recently been announced by Alphabet, Google's parent company, and pharmaceutical giant GlaxoSmithKline (GSK). One of the challenges that scientists face in developing bioelectronic devices is identifying and finding ways to use materials that conduct not only electrons but also ions, as most communication and other processes in the human organism use ionic biosignals (e.g., neurotransmitters). In addition, the materials must be biocompatible. Resolving this challenge is one of the motivations for researchers at São Paulo State University's School of Sciences (FC-UNESP) at Bauru in Brazil. They have succeeded in developing a novel route to more rapidly synthesize and to enable the use of melanin, a polymeric compound that pigments the skin, eyes and hair of mammals and is considered one of the most promising materials for use in miniaturized implantable devices such as biosensors. "All the materials that have been tested to date for applications in bioelectronics are entirely synthetic," said Carlos Frederico de Oliveira Graeff, a professor at UNESP Bauru and principal investigator for the project. "One of the great advantages of melanin is that it's a totally natural compound and biocompatible with the human body: hence its potential use in electronic devices that interface with brain neurons, for example." According to Graeff, the challenges of using melanin as a material for the development of bioelectronic devices include the fact that like other carbon-based materials, such as graphene, melanin is not easily dispersible in an aqueous medium, a characteristic that hinders its application in thin-film production. Furthermore, the conventional process for synthesizing melanin is complex: several steps are hard to control, it can last up to 56 days, and it can result in disorderly structures. In a series of studies performed in recent years at the Center for Research and Development of Functional Materials (CDFM), where Graeff is a leading researcher and which is one of the Research, Innovation and Dissemination Centers (RIDCs) funded by FAPESP, he and his collaborators managed to obtain biosynthetic melanin with good dispersion in water and a strong resemblance to natural melanin using a novel synthesis route. The process developed by the group at CDMF takes only a few hours and is based on changes in parameters such as temperature and the application of oxygen pressure to promote oxidation of the material. By applying oxygen pressure, the researchers were able to increase the density of carboxyl groups, which are organic functional groups consisting of a carbon atom double bonded to an oxygen atom and single bonded to a hydroxyl group (oxygen + hydrogen). This enhances solubility and facilitates the suspension of biosynthetic melanin in water. "The production of thin films of melanin with high homogeneity and quality is made far easier by these characteristics," Graeff said. By increasing the density of carboxyl groups, the researchers were also able to make biosynthetic melanin more similar to the biological compound. In living organisms, an enzyme that participates in the synthesis of melanin facilitates the production of carboxylic acids. The new melanin synthesis route enabled the researchers to mimic the role of this enzyme chemically while increasing carboxyl group density. "We've succeeded in obtaining a material that's very close to biological melanin by chemical synthesis and in producing high-quality film for use in bioelectronic devices," Graeff said. Through collaboration with colleagues at research institutions in Canada, the Brazilian researchers have begun using the material in a series of applications, including electrical contacts, pH sensors and photovoltaic cells. More recently, they have embarked on an attempt to develop a transistor, a semiconductor device used to amplify or switch electronic signals and electrical power. "Above all, we aim to produce transistors precisely in order to enhance this coupling of electronics with biological systems," Graeff said.


Wang Y.,Dalian University of Technology | Wang X.,Center for Research and Development
Mathematical Problems in Engineering | Year: 2010

The nonlinear coupling vibration and bifurcation of a high-speed centrifugal compressor with a labyrinth seal and two air-film journal bearings are presented in this paper. The rotary shaft and disk are modeled as a rigid Jeffcott rotor. Muszynska's model is used to express the seal force with multiple parameters. For air-film journal bearings, the model proposed by Zhang et al. is adopted to express unsteady bearing forces. The Runge-Kutta method is used to numerically determine the vibration responses of the disk center and the bearings. Bifurcation diagrams for transverse motion of the rotor are presented with parameters of rotation speed and pressure drop of the seal. Multiple subharmonic, periodic, and quasiperiodic motions are presented with two seal-pressure drops. The bifurcation characteristics show inherent interactions between forces of the air-film bearings and the seal, presenting more complicated rotor dynamics than the one with either of the forces alone. Bifurcation diagrams are obtained with parameters of pressure drop and seal length determined for the sake of operation safety. © 2010 Y. Wang and X.Wang.


LONDON, UNITED KINGDOM--(Marketwired - Dec 13, 2016) - StaffConnect Group, provider of the world's leading enterprise SaaS mobile employee communications platform, today announced a deal with Tasnee to roll out its platform across their workforce in Saudi Arabia. It is thought this will be the first implementation of its kind to go live in this region and will bring this emerging technology to the forefront of the Employee Communications industry in Middle East countries. Tasnee is Saudi Arabia's first joint-stock industrial company fully owned by the private sector. They required a solution that would unite their global workforce of 7,000 employees and enable effective communication both to, from and between employees. With a high proportion of non-desk employees working in factories and on manufacturing sites, StaffConnect's customer branded mobile app delivers on demand, real-time connectivity wherever the employee is located. StaffConnect was selected for its end to end mobile platform that delivers a leading feature set designed specifically to create a better connected, more engaged workforce. The StaffConnect platform is one of few mobile-first solutions available that effectively tackle the huge proportion of non-desk employees, representing 80% of the world's workforce. Tasnee were particularly impressed with the platform's Communities feature which embraces the 'Voice of the Employee' by encouraging employees to generate and share content to collaborate with colleagues around the world. Tasnee employees can look forward to accessing the Tasnee-branded employee app on their personal smartphones or tablets next year. The secure cloud platform will ensure only current employees are allowed access through Active Directory integration. It also fully supports content in Arabic for those based in the Middle East by utilising the Arabic language and keyboards on their devices. Administrators, managing the app via the Admin Console, will be able to use the Analytics Dashboard to gain greater insights by measuring employee interaction, engagement and sentiment within the company. Karina Dostalova, Global Internal Communications, Tasnee states, "We chose StaffConnect because we have a high proportion of non-desk employees working in remote locations worldwide and needed a way to make them feel more connected and engaged. StaffConnect supported our internal selection process by creating a fully branded demo app that delivered the key features we were looking for. We were also impressed with their AppSuccess program which supports the implementation and internal launch of the app to ensure our employees can quickly get the most out of it." Bulent Osman, Founder and CEO, StaffConnect states, "We are thrilled to have our first customer from the Middle East. Tasnee is a forward thinking organisation that understand the importance of greater employee engagement and are embracing the role of mobile technology in the workplace. "Deloitte research found that business leaders rank employee engagement as the fourth most important trend in 2016 and we are really starting to see evidence of this board level priority across our customers. Organisations are seeing the emergence of mobile technology to deliver the financial and cultural benefits of putting their employees first by creating a united and open environment where every employee has a voice. "Enabling the emotionally connected organisation is our mission at StaffConnect and we are excited that Tasnee are taking their first step toward this by rolling out our mobile platform for all of their employees." About StaffConnect StaffConnect is about enabling the emotionally connected organisation. Empowering your entire workforce to interact, share and collaborate with any form of employee communication, no matter where they are or what they do. With offices in London and San Francisco, StaffConnect is led by a passionate team of internal communications, HR and technology professionals who ensure large organisations can effectively and easily communicate with their employees. www.StaffConnectApp.com About Tasnee Tasnee was established in 1985 as the Saudi private sector's first fully owned joint stock industrial company, with the aim of advancing the economic diversification in Saudi Arabia. Driven by best business practices and the goal of achieving profitable and sustainable growth for its stakeholders and society at large, Tasnee is today Saudi Arabia's second largest industrial company and one of the world's largest producers of titanium dioxide. Tasnee is strongly committed to technology and innovation and supports product innovations through its Nipras Center for Research and Development in Jubail Industrial City. Tasnee allocates 1% of its profits to support charitable and humanitarian projects in Saudi Arabia. www.tasnee.com


News Article | December 20, 2016
Site: phys.org

One of the challenges that scientists face in developing bioelectronic devices is identifying and finding ways to use materials that conduct not only electrons but also ions, as most communication and other processes in the human organism use ionic biosignals (e.g., neurotransmitters). In addition, the materials must be biocompatible. Resolving this challenge is one of the motivations for researchers at São Paulo State University's School of Sciences (FC-UNESP) at Bauru in Brazil. They have succeeded in developing a novel route to more rapidly synthesize and to enable the use of melanin, a polymeric compound that pigments the skin, eyes and hair of mammals and is considered one of the most promising materials for use in miniaturized implantable devices such as biosensors. "All the materials that have been tested to date for applications in bioelectronics are entirely synthetic," said Carlos Frederico de Oliveira Graeff, a professor at UNESP Bauru and principal investigator for the project. "One of the great advantages of melanin is that it's a totally natural compound and biocompatible with the human body: hence its potential use in electronic devices that interface with brain neurons, for example." According to Graeff, the challenges of using melanin as a material for the development of bioelectronic devices include the fact that like other carbon-based materials, such as graphene, melanin is not easily dispersible in an aqueous medium, a characteristic that hinders its application in thin-film production. Furthermore, the conventional process for synthesizing melanin is complex: several steps are hard to control, it can last up to 56 days, and it can result in disorderly structures. In a series of studies performed in recent years at the Center for Research and Development of Functional Materials (CDFM), where Graeff is a leading researcher and which is one of the Research, Innovation and Dissemination Centers (RIDCs) funded by FAPESP, he and his collaborators managed to obtain biosynthetic melanin with good dispersion in water and a strong resemblance to natural melanin using a novel synthesis route. The process developed by the group at CDMF takes only a few hours and is based on changes in parameters such as temperature and the application of oxygen pressure to promote oxidation of the material. By applying oxygen pressure, the researchers were able to increase the density of carboxyl groups, which are organic functional groups consisting of a carbon atom double bonded to an oxygen atom and single bonded to a hydroxyl group (oxygen + hydrogen). This enhances solubility and facilitates the suspension of biosynthetic melanin in water. "The production of thin films of melanin with high homogeneity and quality is made far easier by these characteristics," Graeff said. By increasing the density of carboxyl groups, the researchers were also able to make biosynthetic melanin more similar to the biological compound. In living organisms, an enzyme that participates in the synthesis of melanin facilitates the production of carboxylic acids. The new melanin synthesis route enabled the researchers to mimic the role of this enzyme chemically while increasing carboxyl group density. "We've succeeded in obtaining a material that's very close to biological melanin by chemical synthesis and in producing high-quality film for use in bioelectronic devices," Graeff said. Through collaboration with colleagues at research institutions in Canada, the Brazilian researchers have begun using the material in a series of applications, including electrical contacts, pH sensors and photovoltaic cells. More recently, they have embarked on an attempt to develop a transistor, a semiconductor device used to amplify or switch electronic signals and electrical power. "Above all, we aim to produce transistors precisely in order to enhance this coupling of electronics with biological systems," Graeff said. Explore further: Skin pigment could help strengthen foams and fabrics


Yu J.-Y.,University of California at Irvine | Lu M.-M.,Center for Research and Development | Kim S.T.,University of California at Irvine
Environmental Research Letters | Year: 2012

A newly released reanalysis dataset covering the period 1979-2009 is analyzed to show that the sea surface temperature (SST) variability in the tropical central Pacific is more closely related to the SST variability in the tropical eastern Pacific before 1990 but more closely related to sea level pressure (SLP) variations associated with the North Pacific Oscillation (NPO) after 1990. Only during the period after 1990 can the NPO excite large SST variability in the tropical central Pacific. Related to this change, El Niño Southern Oscillation (ENSO) SST anomalies tend to spread from the eastern to central tropical Pacific before 1990 in a pattern resembling that associated with the Eastern Pacific (EP) type of ENSO, but are more closely connected to SST variability in the subtropical north Pacific after 1990 with a pattern resembling that of the Central Pacific (CP) type of ENSO. This study concludes that the increased influence of the NPO on the tropical Pacific is a likely reason for the increasing occurrence of the CP type of ENSO since 1990. An analysis of the mean atmospheric circulation during these two periods suggests that the increased NPO influence is associated with a strengthening Hadley circulation after 1990. © 2012 IOP Publishing Ltd.


Zuniga R.N.,Center for Research and Development | Pedreschi F.,University of Santiago de Chile
Food and Bioprocess Technology | Year: 2012

The study of the equilibrium is needed not only for modeling of the osmotic process as a unit operation but also for a better understanding of the mass transfer mechanisms involved in this kind of systems. A true equilibrium state usually takes very long time to achieve; therefore, a pseudo-equilibrium state is often employed. Experimental pseudo-equilibrium states for water loss and solid gain during the osmotic dehydration of apple slices (5 × 50 × 50 mm 3) at different osmotic syrup concentrations (30%, 40%, 50%, and 60% (w/w) of sucrose) were evaluated. Four empirical mathematical methods (Slopes, Azuara, Zugarramurdi and Lupín, and Equal concentration) were used in order to calculate the pseudo-equilibrium values obtained and then to compare them against to the experimental ones. Additionally, the effective diffusion coefficients for water and sucrose were calculated by using those pseudo-equilibrium values. Experimental pseudo-equilibrium values increased with concentration of the osmotic syrup, ranged between 24% and 56% for water loss and 11% and 28% for solid gain; the predicted pseudo-equilibrium values followed the same trend. The decreasing order of accuracy for pseudo-equilibrium values and effective diffusion coefficients, among the methodologies evaluated, was Equal concentration method & Azuara method & Slopes method & Zugarramurdi and Lupín method. Although the Equal concentration method has no theoretical accuracy, it is independent of the kinetic data presenting a higher advantage over the other three mathematical methods evaluated. © 2011 Springer Science + Business Media, LLC.

Loading Center for Research and Development collaborators
Loading Center for Research and Development collaborators